Shares of Gilead Sciences (GILD) Rally 0.14%

On a relative basis, the stock has outperformed the S&P 500 by 0.47% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.14% in the last 1 week, and is up 4.86% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.54% and the 50-Day Moving Average is 2.95%.

Gilead Sciences (NASDAQ:GILD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $85.67 and $85.54 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $87.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $86.67, notching a gain of 1.32% for the day. The total traded volume was 11,483,309 . The stock had closed at $85.54 on the previous day.


The company Insiders own 1.4% of Gilead Sciences shares according to the proxy statements. Institutional Investors own 81.77% of Gilead Sciences shares. During last six month period, the net percent change held by insiders has seen a change of -9.29%. In a related news, Milligan John F, director officer (President and CEO) of Gilead Sciences Inc, unloaded 112,000 shares at an average price of $84.62 on July 5, 2016. The total amount of the transaction was worth $9,477,440, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *